RECHOVOT, Israel--(BUSINESS WIRE)--BiondVax Pharmaceuticals Ltd. (TASE:BNDK), an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, announced the successful conclusion of the Company’s second Phase I/II clinical trial of the Multimeric-001 Universal Influenza Vaccine. This second Phase I/II trial was a randomized, single-blind, placebo-controlled, escalating double-dose safety study conducted at the Sourasky Medical Center in Tel Aviv, Israel, in which a total of 60 participants, males and females aged 55-75, received two intramuscular injections containing the vaccine, either with or without adjuvant, and at two different dose levels. This was then followed by an administration of a commercially available seasonal influenza vaccine.
